Logo image of VKTX

VIKING THERAPEUTICS INC (VKTX) Stock Fundamental Analysis

USA - NASDAQ:VKTX - US92686J1060 - Common Stock

35.22 USD
+0.29 (+0.83%)
Last: 10/29/2025, 5:09:39 PM
35.16 USD
-0.06 (-0.17%)
After Hours: 10/29/2025, 5:09:39 PM
Fundamental Rating

3

VKTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While VKTX has a great health rating, there are worries on its profitability. VKTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VKTX has reported negative net income.
VKTX had a negative operating cash flow in the past year.
In the past 5 years VKTX always reported negative net income.
VKTX had a negative operating cash flow in each of the past 5 years.
VKTX Yearly Net Income VS EBIT VS OCF VS FCFVKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of VKTX (-32.11%) is better than 65.36% of its industry peers.
Looking at the Return On Equity, with a value of -33.29%, VKTX is in the better half of the industry, outperforming 75.84% of the companies in the same industry.
Industry RankSector Rank
ROA -32.11%
ROE -33.29%
ROIC N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
VKTX Yearly ROA, ROE, ROICVKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

VKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VKTX Yearly Profit, Operating, Gross MarginsVKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, VKTX has more shares outstanding
VKTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VKTX Yearly Shares OutstandingVKTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VKTX Yearly Total Debt VS Total AssetsVKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 87.94 indicates that VKTX is not in any danger for bankruptcy at the moment.
VKTX's Altman-Z score of 87.94 is amongst the best of the industry. VKTX outperforms 98.88% of its industry peers.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 87.94
ROIC/WACCN/A
WACCN/A
VKTX Yearly LT Debt VS Equity VS FCFVKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

VKTX has a Current Ratio of 28.34. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 28.34, VKTX belongs to the best of the industry, outperforming 97.57% of the companies in the same industry.
A Quick Ratio of 28.34 indicates that VKTX has no problem at all paying its short term obligations.
VKTX has a Quick ratio of 28.34. This is amongst the best in the industry. VKTX outperforms 97.57% of its industry peers.
Industry RankSector Rank
Current Ratio 28.34
Quick Ratio 28.34
VKTX Yearly Current Assets VS Current LiabilitesVKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for VKTX have decreased strongly by -127.96% in the last year.
EPS 1Y (TTM)-127.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VKTX will show a small growth in Earnings Per Share. The EPS will grow by 4.59% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-147.07%
EPS Next 2Y-78.61%
EPS Next 3Y-52.27%
EPS Next 5Y4.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VKTX Yearly Revenue VS EstimatesVKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
VKTX Yearly EPS VS EstimatesVKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VKTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VKTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VKTX Price Earnings VS Forward Price EarningsVKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VKTX Per share dataVKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as VKTX's earnings are expected to decrease with -52.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-78.61%
EPS Next 3Y-52.27%

More info and screens

0

5. Dividend

5.1 Amount

VKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIKING THERAPEUTICS INC

NASDAQ:VKTX (10/29/2025, 5:09:39 PM)

After market: 35.16 -0.06 (-0.17%)

35.22

+0.29 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-22 2025-10-22/amc
Earnings (Next)02-03 2026-02-03/amc
Inst Owners67.53%
Inst Owner Change-0.49%
Ins Owners2.15%
Ins Owner Change0.28%
Market Cap3.96B
Revenue(TTM)N/A
Net Income(TTM)-237394000
Analysts86.09
Price Target95.12 (170.07%)
Short Float %23.21%
Short Ratio3.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.29%
Min EPS beat(2)-27.37%
Max EPS beat(2)-17.21%
EPS beat(4)0
Avg EPS beat(4)-20.55%
Min EPS beat(4)-27.37%
Max EPS beat(4)-13.7%
EPS beat(8)4
Avg EPS beat(8)-3.61%
EPS beat(12)5
Avg EPS beat(12)-3.4%
EPS beat(16)7
Avg EPS beat(16)-1.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.59%
EPS NQ rev (1m)3.4%
EPS NQ rev (3m)-38.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-28.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.55
P/tB 5.55
EV/EBITDA N/A
EPS(TTM)-2.12
EYN/A
EPS(NY)-3.19
Fwd EYN/A
FCF(TTM)-2
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS0
BVpS6.34
TBVpS6.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.11%
ROE -33.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 28.34
Quick Ratio 28.34
Altman-Z 87.94
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-127.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.18%
EPS Next Y-147.07%
EPS Next 2Y-78.61%
EPS Next 3Y-52.27%
EPS Next 5Y4.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-105.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-106.94%
EBIT Next 3Y-43.61%
EBIT Next 5Y-26.07%
FCF growth 1Y-236.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-236.85%
OCF growth 3YN/A
OCF growth 5YN/A

VIKING THERAPEUTICS INC / VKTX FAQ

What is the ChartMill fundamental rating of VIKING THERAPEUTICS INC (VKTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VKTX.


What is the valuation status for VKTX stock?

ChartMill assigns a valuation rating of 0 / 10 to VIKING THERAPEUTICS INC (VKTX). This can be considered as Overvalued.


What is the profitability of VKTX stock?

VIKING THERAPEUTICS INC (VKTX) has a profitability rating of 1 / 10.


How financially healthy is VIKING THERAPEUTICS INC?

The financial health rating of VIKING THERAPEUTICS INC (VKTX) is 8 / 10.